Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
TROW is losing ground into its October 29 print, with the stock down 4.6% over the past month to $101.39, and analysts across the Street moving in one direction: lower.
The analyst picture has turned notably one-sided this week. Barclays cut its target to $102 on October 14, a level that now sits barely above the current price, while maintaining an Underweight rating. JP Morgan trimmed to $106, also Underweight, a day earlier. BMO Capital made the sharpest single move, dropping its target from $120 to $110 while staying at Market Perform. TD Cowen and Evercore ISI both nudged targets down to $109 in the past week as well. The mean target across the Street is now $105.92, just 4.5% above where the stock trades. The direction of travel has been consistently downward: Morgan Stanley lowered to $110 in late September, Evercore had already trimmed twice since August. UBS is the lone contrarian note, assuming coverage this week with a Neutral rating and a $107 target, stepping up from what had been a Sell. Bears point to an AUM-driven EPS miss and a core fee rate running below expectations at 0.396%, alongside margin deterioration that raises questions about where earnings settle. Bulls counter with $2.5 billion in ETF net inflows last quarter and $1.767 trillion in AUM, a large share of it in sticky retirement accounts. At a PE of roughly 9.9 and EV/EBITDA of 6.3, both compressing over the past month, the valuation is inexpensive. The dividend factor score ranks in the 86th percentile, and historical EPS surprise lands at the 80th, even as forward earnings momentum sits in the bottom quartile.
Short interest has continued building, a trend consistent with what was noted in the October 11 article. The position has grown a further 2.5% on the week to reach 12.4% of free float, with the ORTEX short score ticking up steadily to 72.9 from 72.4 two weeks ago. The bears are adding, not retreating. Yet the lending market remains relaxed. Availability has eased slightly to 287%, meaning roughly three shares are available to borrow for every one already shorted, and cost to borrow is just 0.53%. The 52-week tightest point was 234% availability, reached in mid-September, so there is no borrow squeeze anywhere in sight. Days to cover at 17.2 underscores how slow any unwind would be, but there is nothing in the borrow market that forces one. Options positioning has diverged from the short book. The put/call ratio at 0.75 is slightly below its 20-day average of 0.77, a mild lean toward calls rather than puts, and well below the 0.97 level that dominated through September. Options traders are not buying the bear case as aggressively as short sellers.
An index rebalance wrinkle adds a mechanical dimension to watch. ORTEX puts a 47% probability on TROW being added to the CRSP US Small index at the December 2026 Quarterly Review, with a simultaneous reduction in its CRSP US Large and US Mid weightings. The stock is currently trading 2% above the entry price line at $99.36. If it qualifies, index trackers would need to buy roughly $339 million worth of shares over approximately two days of normal volume. At the same time, forced selling from the large and mid-cap indices would amount to $270 million combined. The rank date is December 4, with a trade date of December 22. This is a probability, not a confirmed outcome, and the stock needs to hold above $99.36 to stay in contention.
Prior earnings prints provide sober context. T. Rowe fell 4.8% the day after its July 2026 results, and was down 4.4% five days later. A similar pattern played out at the prior quarter's print, with a 6.0% one-day decline. With fifteen days to the October 29 release, the convergence of analyst target cuts, steadily rising short interest, and a stock that has lost ground for four consecutive weeks sets up a print where execution on fees and margins will carry significant weight.
See the live data behind this article on ORTEX.
Open TROW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
